Temozolomide drug page Clinical trials

Trials with Temozolomide

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

15Trials
7Recruiting
18Countries
2.687Planned patients

Showing 1–15 of 15

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Recruiting Phase 2 260 patients NCT07492680

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…

United States, Belgium, Canada, China and 8 more Jul 2026 – May 2032 Interventional
The Sagittarius Trial
Recruiting Phase 3 700 patients NCT06490536

Background \& Rationale: Colon cancer is a leading cause of cancer deaths, with a high recurrence rate in stage II high-risk and stage III patients due to undetectable micro-metastases. Liquid biopsy (LB) detects residual cancer DNA post-…

Germany, Italy, Spain Oct 2024 – Sept 2028 Interventional
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Recruiting Phase 1 42 patients NCT05691491

This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metasta…

United States Sept 2023 – Mar 2027 Interventional
Combined with: Tuvusertib
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Recruiting Phase 1 695 patients NCT05417594

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…

United States, Australia, Germany, South Korea and 3 more Jun 2022 – Oct 2027 Interventional
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
Recruiting Phase 2 21 patients NCT05136326

In patients with locally advanced rectal cancer (LARC), preoperative chemo-radiotherapy (CTRT) is considered the standard of care. Preoperative CTRT approach often results in a significant tumor downstaging and local control, with evidence…

Italy Dec 2021 – Dec 2026 Interventional
Combined with: Capecitabine
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Recruiting Phase 1 27 patients NCT04689347

An upfront-intensified treatment combining all the three active cytotoxic agents in metastatic colorectal cancer (mCRC) including fluoropyrimidines, oxaliplatin, irinotecan (FOLFOXIRI) plus antiangiogenic blockade with bevacizumab signific…

Italy Jan 2021 – Jan 2027 Interventional
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Recruiting Phase 1 411 patients NCT03715933

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

United States, France, Italy, Netherlands and 2 more Oct 2018 – Jun 2029 Interventional
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
Finished Phase 2 18 patients NCT04457284

This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The resea…

United States Nov 2020 – Jul 2026 Interventional
Combined with: CisplatinNivolumab
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Finished Phase 2 11 patients NCT04166435

This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.

United States Jun 2020 – Jun 2023 Interventional
Combined with: Olaparib
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer
Finished Phase 2 135 patients NCT03832621

This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27 patients with MSS, MGMT-silenced mCRC with initial clinical benef…

Italy Mar 2019 – Sept 2021 Interventional
Combined with: IpilimumabNivolumab
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Finished Phase 2 102 patients NCT03519412

In this study, MMRd metastatic colorectal cancer (mCRC) patients who failed standard therapies will undergo treatment with pembrolizumab, while RAS-extended mutated MMR-proficient mCRC patients will be tested for o6-methylguanine-DNA-methy…

Italy Jan 2019 – Dec 2024 Interventional
Combined with: Pembrolizumab
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients
Finished Phase 2 82 patients NCT02414009

Open-label, randomized, multicenter, Phase II trial designed to estimate the efficacy of CAPTEM versus FOLFIRI as second line treatment in MGMT methylated, RAS mutated advanced CRC patients who have progressed on or after first-line oxalip…

Italy Sept 2014 – Jul 2019 Interventional
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Finished Phase 1 22 patients NCT01781403

The investigators planned a phase I study of preoperative CRT with capecitabine plus temozolomide inpatients with locally advanced resectable rectal cancer: 1) the role of temozolomide as a radiosensitizer has been well established, 2) hyp…

South Korea May 2013 – May 2016 Interventional
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Finished Phase 2 75 patients NCT01051596

People with colorectal cancer that cannot be cured by surgery are being asked to participate in this study. The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and temozolomide for pati…

United States Sept 2009 – Dec 2013 Interventional
Combined with: Veliparib
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
Finished Phase 2 86 patients NCT00423150

This study is proposed to evaluate the efficacy and safety of temozolomide, an oral anti-cancer agent, in a participant population selected for a biomarker. Participants with colorectal cancer, non-small-cell lung cancer, head and neck can…

Jan 2007 – Jun 2009 Interventional

Where the recruiting trials are